Doxorubicin Hydrochloride Liposome Injection

DRUG14 trials

Sponsors

University of California, San Francisco, Dr. Reddy's Laboratories Limited, Beijing Friendship Hospital, Hebei Medical University Fourth Hospital, Ayana Pharma Ltd.,

Conditions

Advanced Breast CancerAdvanced Malignant TumorsBioequivalenceBreast CancerEpithelial Ovarian CancerFallopian Tube CancerHemophagocytic LymphohistiocytosisHormone-receptor Positive Breast Cancer

Phase 1

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

CompletedNCT02260544

Dr. Reddy's Laboratories LimitedOvarian Epithelial Cancer Recurrent

Start: 2014-07-31End: 2015-08-31Updated: 2016-09-23

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

CompletedNCT03681548

Ayana Pharma Ltd.,Ovarian Cancer Recurrent

Start: 2018-08-29End: 2019-03-07Updated: 2019-11-20

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients

Shenzhen Kangzhe Pharmaceutical Co., Ltd.Breast Cancer, Ovarian Cancer

Start: 2021-07-28End: 2022-04-30Target: 80Updated: 2022-03-10

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

CompletedNCT06098599

Luye Pharma Group Ltd.Advanced Breast Cancer

Start: 2022-05-17End: 2023-02-09Updated: 2023-10-24

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

RecruitingNCT06840002

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Ovarian Cancer

Start: 2025-03-18End: 2026-07-31Target: 150Updated: 2025-09-30

Phase 2

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

TerminatedNCT00632827

University of California, San FranciscoPeripheral T-Cell Lymphoma

Start: 2008-07-01End: 2016-06-23Updated: 2020-04-27

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Active, not recruitingNCT04872985

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBreast Cancer, Hormone-receptor Positive Breast Cancer

Start: 2021-04-20End: 2028-12-31Target: 140Updated: 2026-01-06

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Start: 2021-09-30End: 2024-01-31Target: 126Updated: 2021-07-30

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Fudan UniversityAdvanced Malignant Tumors

Start: 2000-03-01End: 2022-11-01Target: 30Updated: 2022-04-29

Phase 3

L-DEP as an Initial Treatment for EBV-HLH

Beijing Friendship HospitalHemophagocytic Lymphohistiocytosis

Start: 2016-09-30End: 2019-09-30Target: 120Updated: 2016-09-23

A Study of SHR-A1811 in Subjects With Ovarian Cancer

RecruitingNCT06828354

Jiangsu HengRui Medicine Co., Ltd.Ovarian Cancer

Start: 2025-03-13End: 2027-12-31Target: 300Updated: 2025-03-24

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

RecruitingNCT07362914

Fudan UniversityBreast Cancer

Start: 2025-03-07End: 2027-01-30Target: 182Updated: 2026-01-23

Unknown Phase

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

CompletedNCT03017404

Hebei Medical University Fourth HospitalBreast Cancer

Start: 2015-05-31End: 2016-07-31Updated: 2017-01-11

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

CompletedNCT04460820

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Bioequivalence

Start: 2019-07-04End: 2019-12-23Updated: 2020-07-08